Comprehensive Notes on Antidepressants, Anxiolytics, and Mood Stabilizers

Antidepressants, Anxiolytics, and Mood Stabilizers: Comprehensive Study Notes

Overview context
- Medications discussed include antidepressants (TCAs, SSRIs, SNRIs/atypicals), antianxiety agents (benzodiazepines and alternatives), and mood stabilizers (lithium and anticonvulsants used as mood stabilizers).
- Some drugs are also used for non-depressive indications (e.g., neuropathic pain, anxiety disorders, insomnia, smoking cessation, seasonal depression).
- A recurring theme: many antidepressants take time to work; clinical effects may require patience from patients.
General mechanism: reuptake blockade and neurotransmitter availability
- Many antidepressants block reuptake of key neurotransmitters to increase their availability:
- Dopamine
- Serotonin
- Norepinephrine
- By blocking reuptake, these medications make these neurotransmitters more available in the synaptic cleft to exert their effects.
- Therapeutic effects typically require time to develop; practically, "it takes up to $4 \text{ weeks}$ " for broad therapeutic effects to emerge.
- This applies to many antidepressants, including SSRIs and TCAs.
Tricyclic Antidepressants (TCAs)
- Anticholinergic effects (from TCAs) include:
- Dry mouth, dry eyes, urinary retention, constipation
- Management/education for anticholinergic side effects (similar to education given with antipsychotics):
- Use hard candy for dry mouth
- Ensure adequate fluids, high fiber diet
- Use eye drops for dry eyes
- Weight changes are possible (weight gain or fluctuations); encourage appropriate exercise and diet to mitigate.
- Toxicity risk:
- TCAs can reach toxic blood levels, potentially causing serious dysrhythmias and even death if not monitored.
- Regular monitoring of blood levels is essential when starting or adjusting therapy.
- Prescription duration and follow-up:
- Not always a full $90-\text{day}$ supply; often initial prescriptions are $30\text{ days}$ with follow-up to assess efficacy and adjust dosing, possibly requiring a blood level check.
SSRIs (Selective Serotonin Reuptake Inhibitors)
- Mechanism: block reuptake of serotonin to increase its availability; primarily target serotonin system.
- Common SSRI examples and brand names:
- Citalopram — Celexa
- Escitalopram — Lexapro
- Sertraline — Zoloft
- Paroxetine — Paxil
- How to recognize SSRIs vs TCAs (naming clues):
- Endings like -pram (e.g., citalopram, escitalopram) help identify SSRIs; however, some exceptions exist.
- Primary indications:
- Widely used for depression; commonly used for anxiety disorders as well as depression.
- Side effects and considerations:
- Sexual dysfunction can be a prominent issue, especially in males, which may affect adherence.
- Serotonin syndrome risk (especially with polypharmacy or serotonergic agents):
  - Signs to educate patients to watch for include increased confusion, insomnia, rising blood pressure, headaches, and diaphoresis (heavy sweating).
  - If suspected, seek medical evaluation promptly.
- Serotonin withdrawal/Discontinuation syndrome if stopping abruptly; tendency to experience unease or other symptoms; require gradual tapering.
- Withdrawal/discipline for switching drugs: if stopping to start another antidepressant or to discontinue therapy, taper over $2 \text{ weeks}$ to $1 \text{ month}$ to reduce risks of withdrawal and other adverse effects.
- Drug interactions and OTC considerations:
- Watch for interactions with OTC herbal supplements such as St. John’s Wort; discontinue such supplements when initiating an SSRI or prior to switching to another antidepressant to avoid interactions.
- Weight management:
- Weight fluctuations are possible; address with exercise and diet; may involve referrals to a dietitian for weight maintenance.
- Monitoring and safety:
- Because patients may not feel full effects within $30\text{ days}$ , emphasize adherence and follow-up.
Atypical antidepressants (still antidepressants but with unique properties)
- Venlafaxine — Effexor; Duloxetine — Cymbalta
- Both have serotonin reuptake inhibition and also affect norepinephrine to varying degrees (often categorized as SNRIs or atypical serotonergic agents).
- Trazodone
- Has a sedative component and is often used to treat insomnia alongside depressive symptoms.
- Typically prescribed at night due to sedative effects.
- Not uncommonly combined with another antidepressant to cover daytime symptoms.
- Priapism risk in males; if prolonged erection occurs, urgent medical care is required (seek ER help).
- Mirtazapine — Remeron
- Atypical antidepressant with appetite-stimulating properties; often used in elderly patients.
- May be used to address weight loss by improving appetite; sometimes used in conjunction with dietary changes or nutrition referrals.
- Bupropion — Wellbutrin
- Uses include depression treatment, seasonal affective disorder (seasonal depression), and smoking cessation aid.
- Weight loss potential sometimes discussed with patients.
- Suicidal ideation risk during early treatment
- Regardless of the antidepressant, initial weeks to months require monitoring for renewed suicidal ideation.
- If suicidal ideation is detected, providers may escalate care (turther psychiatric treatment, possible inpatient or outpatient intervention) without necessarily stopping the antidepressant; safety planning and additional supports are implemented.
Antianxiety agents
- Benzodiazepines (often referred to as benzos)
- Common agents include lorazepam and alprazolam (note: transcript mistakenly mentions “Orazepam”; correct names are lorazepam and alprazolam).
- Mechanism: CNS depression and GABA potentiation to reduce anxiety and CNS arousal.
- Onset: rapid; effects can be observed within $5 \text{ to } 30 \text{ minutes}$ depending on route of administration (oral vs IV).
- Uses:
  - Anxiety disorders
  - Alcohol or drug withdrawal (e.g., delirium tremens management)
  - Preoperative or pre-procedural sedation (e.g., MRI)
- Important risks and nursing considerations:
  - Very common cause of dependence and tolerance; intended for short-term use only due to dependence risk.
  - Sedation can impair activities requiring alertness (e.g., driving, operating heavy machinery).
  - Potential for anterograde amnesia (new memory formation impaired) and paradoxical excitation (jitteriness, agitation) in some patients.
  - Interactions: enhanced CNS depression with concurrent CNS depressants (e.g., alcohol).
  - Regular medication reviews are important (especially in long-term care) to assess continuation or tapering needs and to consider gradual dose reductions (GDRs).
  - Overdose management: antidote is Flumazenil; other measures may include gastric lavage and activated charcoal.
- Buspirone — Buspar
- A non-benzodiazepine anxiolytic.
- Mechanism: partial agonist that modulates serotonin and dopamine systems.
- Onset: slower; about $7 \text{ to } 10 \text{ days}$ to see benefit.
- Side effects may include dizziness and agitation; less risk of dependence compared to benzodiazepines.
Mood stabilizers
- Purpose: reduce the frequency and intensity of manic episodes in bipolar disorder and some anxiety states.
- Lithium
- A classic mood stabilizer with a very narrow therapeutic range; requires regular blood level monitoring.
- Therapeutic ranges vary by treatment state:
  - Acute treatment: $\text{higher range in the acute phase}$ (documented as rising during acute episodes in planning/implementation).
  - Maintenance phase: $\text{lower range}$ to maintain stability.
- Neurotransmitter influence: affects several neurotransmitter systems including norepinephrine, serotonin, dopamine, GABA; also interacts with glutamate (newer emphasis on glutamate signaling in mood regulation).
- Monitoring and labs:
  - Blood levels drawn frequently when starting (up to $1\sim2\text{ times per week}$ initially) and then periodically (often monthly) once stable.
  - Continuous monitoring is essential due to narrow therapeutic window and potential toxicity.
- Safety and lifestyle considerations:
  - Adequate hydration and a balanced sodium intake are important; sodium and water balance influence lithium levels.
  - In cases of lithium toxicity: promptly discontinue lithium and ensure aggressive hydration; if toxicity suspected, dialysis may be considered in severe cases.
  - Typical daily fluid recommendation: approximately $2 \text{ to } 3\,\text{liters/day}$ unless contraindicated (e.g., kidney disease).
- Anticonvulsants as mood stabilizers
- Valproate (Depakote), Carbamazepine, Lamotrigine (Lamictal), Levetiracetam (Keppra), among others, are used as mood stabilizers when lithium is not suitable or as adjuncts.
- Common themes:
  - Many require regular blood levels to monitor therapeutic range and avoid toxicity.
  - Side effects can include weight gain, headaches, confusion; ongoing monitoring for cognitive or other adverse effects.
  - Like lithium, they are used to prevent mood fluctuation and stabilize mood in bipolar disorder.
- Overdose and countermeasures (context-specific):
  - Some anticonvulsant overdoses may require specific interventions or supportive care; in certain cases, dialysis can be used to remove certain anticonvulsants from the bloodstream.
- Other considerations related to mood stabilization therapy
- Some discussions mention calcium channel blockers (ending in -dipine, e.g., amlodipine, nifedipine) as unrelated to mood stabilization but relevant in other comorbid conditions (blood pressure). Verapamil and diltiazem are also calcium channel blockers; their relevance to mood stabilization is limited and not first-line in this context.
Key clinical concepts and practical implications
- Medication education and patient safety
- Many antidepressants require patience and adherence due to delayed onset of therapeutic effects.
- Patients should be educated on potential sexual side effects, withdrawal syndromes, risk of suicidality, and the importance of adherence and follow-up.
- Drug interactions and comorbidity considerations
- Herbal supplements (e.g., St. John’s Wort) can interact with SSRIs and other antidepressants; a thorough medication reconciliation should include OTC and herbal products.
- CNS depressants (alcohol, sedatives) can potentiate the effects of benzodiazepines.
- Monitoring and follow-up structure
- Initial frequent lab monitoring for lithium and certain anticonvulsants (blood levels every 1–2 weeks during initiation, then monthly when stable).
- Regular medication reviews (e.g., every 6–12 months in long-term care) to assess continued need, dosing, and potential tapering or dose reductions.
- Safety planning for suicidal ideation and psychiatric crises
- Early phases of antidepressant therapy require close monitoring for renewed suicidal thoughts; escalation to higher levels of psychiatric care may be warranted but does not always necessitate stopping the antidepressant.
Quick reference: key numerical reminders
- Onset of antidepressants generally up to $4 \text{ weeks}$ for therapeutic effects.
- SSRIs: withdrawal/taper recommendations typically $2 \text{ weeks}$ to $1 \text{ month}$ when changing medications.
- Benzodiazepines: onset as quick as $5 \text{ to } 30 \text{ minutes}$ depending on route.
- Lithium monitoring: frequent early lab monitoring (up to $1\sim2\text{ times/week}$ during initiation) and then monthly once stable; aim for a stable, clinically appropriate blood level; hydration and sodium balance are important to avoid toxicity.
- Trazodone dosing for sleep is typically nighttime due to sedative effects (often used with another antidepressant in the day).